Campbell & CO Investment Adviser LLC Prothena Corp Public LTD CO Transaction History

Campbell & CO Investment Adviser LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $5,413 - $6,760	104 Added 1.23%	8,527 $513,000
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $211,922 - $510,686	8,423 New	8,423 $511,000
Q4 2021 Feb 10, 2022	SELL	$42.11 - $73.26 $353,724 - $615,384	-8,400 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$48.2 - $78.89 $404,880 - $662,676	8,400 New	8,400 $598,000
Q3 2020 Oct 15, 2020	SELL	$9.93 - $13.47 $367,866 - $499,009	-37,046 Closed	0 $0
Q2 2020 Jul 29, 2020	BUY	$9.56 - $12.51 $354,159 - $463,445	37,046 New	37,046 $388,000
Q4 2019 Jan 23, 2020	SELL	$7.48 - $17.01 $358,299 - $814,796	-47,901 Closed	0 $0
Q3 2019 Oct 16, 2019	BUY	$6.89 - $10.45 $190,170 - $288,430	27,601 Added 135.97%	47,901 $376,000
Q2 2019 Jul 10, 2019	BUY	$8.85 - $12.49 $179,655 - $253,547	20,300 New	20,300 $215,000

185

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $668M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.